FDA approves bosutinib for pediatric patients with chronic myelogenous
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
Related Articles
FDA Grand Rounds
Highlights monthly webcast presentations for CE credit by FDA scientists from across agency on their cutting-edge scientific research
Lock
This will be the second of three public meetings hosted by the President’s Cancer Panel on the topic of Reducing Cancer Care Inequities: Leveraging Technology…
Getting vaccinated in fall can lower your chances of getting the flu
Haven’t had your flu shot yet? It’s not too late. Every flu season is different. Your best defense against the flu is to get a…
FDA grants accelerated approval to pirtobrutinib
On December 1, 2023, the Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with chronic lymphocytic leukemia…
Project Livin’ Label
Project Livin’ Label aims to foster broad understanding of the oncology product label and increase awareness of recent oncology drug FDA approvals.
Special Sessions will kick off Symposium with hot topics in breast cancer care and prevention – SABCS Meeting News
Three concurrent Special Sessions on Tuesday will cover topics including new drug approvals for metastatic breast cancer and the prevention, early detection, and interception of…
Public meeting: FDA Rare Disease Day 2024
FDA will host Rare Disease Day, a virtual public meeting, on March 1, 2024 in global observance of Rare Disease Week.